Empagliflozin in Heart Failure Dialysis Patients

Sponsor
Shahid Beheshti University of Medical Sciences
Study ID
NCT05967156
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin10Mg Tab — DRUG
    10 mg daily

Study Details

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Key Dates

Start date
Jun 1, 2023
Status verified
Jun 2025
Primary completion
Jun 1, 2025
Completion
Jun 3, 2025

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    Heart failure dialysis patients will be treated with Empagliflozin

Primary Outcome Measure

Brain Natriuretic Peptide [ Time Frame: one month after administration ]

Related Studies